

6th November, 2006

Press Release

The Genetics Company Inc. enters distributorship agreement with South Korean BiMeince Corporation.

The Genetics Company Inc., a privately held Swiss company focusing on the research, development and commercialization of products for the diagnosis, monitoring and therapy of patients suffering from Alzheimer's disease and cancer, is pleased to announce the closing of a distributorship agreement with BiMeince Corporation a leading distributor of pre-clinical and clinical research products. Within the scope of this agreement, The Genetics Company will supply BiMeince with its innovative beta-Amyloid (A β) detection tools for the diagnosis and research of neurodegenerative diseases, such as Alzheimer's disease and stroke, for distribution in South Korea.

Please find enclosed our press release. Thank you for your consideration and kind regards,



Dr. Harald Eistetter, CEO
eistetter@the-genetics.com

www.the-genetics.com

PRESS RELEASE

Zurich, Switzerland – 6th November, 2006

The Genetics Company Inc. enters distributorship agreement with South Korean BiMeince Corporation.

The Genetics Company Inc., a privately held Swiss company focusing on the research, development and commercialization of products for the diagnosis, monitoring and therapy of patients suffering from Alzheimer's disease and cancer, is pleased to announce the closing of a distributorship agreement with BiMeince Corporation, a leading distributor of pre-clinical and clinical research products. Within the scope of this agreement, The Genetics Company will supply BiMeince with its innovative beta-Amyloid (A β) detection tools for the diagnosis and research of neurodegenerative diseases, such as Alzheimer's disease and stroke, for distribution in South Korea.

The Genetics Company's diagnostic and research tools enable the specific and selective detection of variants of human beta-Amyloid (A β), a key protein involved in the pathogenesis of several neurodegenerative diseases. The Company's products include very sensitive and reliable enzyme-linked immunosorbent assay (ELISA)-based test kits for the quantification of A β 40 and A β 42 in either cerebrospinal fluid (CSF) or plasma and cell lysate samples. While the corresponding A β 42/40 ratio has been validated by several recent studies as a superior biomarker for the diagnosis of incipient AD, the Company's test kits are also successfully used in clinical trials as drug monitoring tools or for pre-clinical research and development of A β lowering drugs. In addition, The Genetics Company's portfolio of A β -quantifying tools is complemented by highly selective monoclonal antibodies for the detection of A β , in particular A β 40 and A β 42.

Kim, Jhin-Chul, President and General Manager of BiMeince commented: "The Genetics Company's high quality research and diagnosis products will enable us to participate in and further develop the emerging field of neurodegenerative diseases in South Korea, especially in the areas of academic and industrial research as well as for in vitro diagnosis". Dr. Sebastian Breuer, Program Manager Diagnostics at The Genetics Company added: "With BiMeince we are pleased to have found the ideal partner to enter the South Korean market. This cooperation enables us to cover one of the most attractive health care markets in South East Asia".

About BiMeince Corporation

BiMeince is a South Korean distributor specialized on research and medical products. The company is headquartered in Suwon-City and hence in closer proximity to the capital Seoul. Currently, BiMeince has four highly competent and experienced employees as sales representatives and advisors. In addition, BiMeince has cooperation agreements with several sub-distributors in South Korea. The product-portfolio of BiMeince is focused on diagnostic

tools for the detection of microbial as well as protein pathogens. Customers of BiMeince are mainly academic and governmental research institutions as well as hospitals.

About The Genetics Company, Inc.

The Genetics Company, Inc. is a dedicated team of entrepreneurs and scientists focusing on the research, development and commercialization of innovative products for the diagnosis, therapy and therapy monitoring of patients suffering from neurodegenerative disease and cancer. Apart from a set of worldwide unique diagnostic kits and tools for the diagnosis and monitoring of patients suffering from Alzheimer's disease (AD), the Company has identified small molecule inhibitors of BACE (beta-Amyloid converting enzyme). It has also identified small molecule inhibitors of two proprietary targets within the Wnt-pathway, which is believed to play a crucial role in colon cancer. Headquartered in Zurich-Schlieren, Switzerland, the Company currently employs a staff of 24.

For additional information about BiMeince Corporation please contact:

*Kim, Jhin-Chul
President & General Manager
BiMeince Corporation
2F, Bi-Bong Bldg
In-Kye Dong, Pal-Dal Gu
Suwon City, Kyeong-Gi Do
South Korea
Tel: +82-31-234-2710
Fax: +82-31-234-3260
E-mail: jhinchul@bimeince.com
Web: www.bimeince.com*

For corporate information about The Genetics Company please contact:

*Dr. Harald Eistetter
The Genetics Company
Wagistrasse 27
CH-8952 Schlieren/Zürich
Switzerland
Tel: +41-44-2002222
Fax: +41-44-2002211
E-mail: eistetter@the-genetics.com
Web: www.the-genetics.com*

For further information about The Genetics Company's products please contact:

*Oliver Wildanger
The Genetics Company
Tel: +41-44-2002266
Fax: +41-44-2002211
E-mail: wild@the-genetics.com*